Jiangsu Jibeier Pharmaceutical Co., Ltd.
Shanghai Stock Exchange 688566.SS
Jiangsu Jibeier Pharmaceutical Co., Ltd. Return on Capital Employed (ROCE) for the year ending December 31, 2023: 12.67%
Jiangsu Jibeier Pharmaceutical Co., Ltd. Return on Capital Employed (ROCE) is 12.67% for the year ending December 31, 2023, a 49.84% change year over year. Return on capital employed assesses profitability against invested capital; higher ROCE signals efficient capital use.
-
Jiangsu Jibeier Pharmaceutical Co., Ltd. Return on Capital Employed (ROCE) for the year ending December 31, 2022 was 8.45%, a 36.15% change year over year.
-
Jiangsu Jibeier Pharmaceutical Co., Ltd. Return on Capital Employed (ROCE) for the year ending December 31, 2021 was 6.21%, a -24.35% change year over year.
-
Jiangsu Jibeier Pharmaceutical Co., Ltd. Return on Capital Employed (ROCE) for the year ending December 31, 2020 was 8.21%, a -66.45% change year over year.
-
Jiangsu Jibeier Pharmaceutical Co., Ltd. Return on Capital Employed (ROCE) for the year ending December 31, 2019 was 24.46%, a -10.06% change year over year.
Key data
| Date | Return on Capital Employed (ROCE) | Interest Coverage Ratio | Debt to Equity Ratio | Return on Common Equity |
|---|
Market news
Loading...
Don’t Miss A Beat
Shanghai Stock Exchange: 688566.SS
| CEO | Mr. Zhongyi Geng |
| IPO Date | May 18, 2020 |
| Location | China |
| Headquarters | High-tech Industrial Development Zone |
| Employees | 1,445 |
| Sector | Healthcare |
| Industries | |
Description
Jiangsu Jibeier Pharmaceutical Co., Ltd., a pharmaceutical company, engages in the research, development, production, and sale of chemical preparations, proprietary Chinese medicine preparations, and bulk medicines. The company's products cover various therapeutic areas, such as improving white blood cells, enhancing immunity, treating joint diseases, anti-hypertension, anti-eye infections, treating bronchitis, protecting liver function, etc. It is also developing drugs for the treatment of depression, tumors, stomach diseases, and other diseases. The company was founded in 2001 and is based in Zhenjiang, China.
Key trends
Past 5 years
StockViz Staff
February 2, 2025
Any question? Send us an email